Peritumoral indoleamine 2,3‐dioxygenase expression in melanoma: an early marker of resistance to immune control?
British Journal of Dermatology2014Vol. 171(5), pp. 987–995
Citations Over TimeTop 13% of 2014 papers
Inès Chevolet, Reinhart Speeckaert, Marc Haspeslagh, Bart Neyns, Vibeke Krüse, Max Schreuer, Mireille Van Gele, Nanja van Geel, Liève Brochez
Abstract
Endothelial IDO expression is highly consistent in primary, sentinel and metastatic tissues of patients with melanoma, indicating that immune suppression in melanoma is determined very early in the disease course. This supports that IDO expression in melanoma is a marker of antitumour immune response with an independent prognostic value.
Related Papers
- → PD-L1, CD4+, and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Expression Profiles in Melanoma Tumor Microenvironment Cells(2023)23 cited
- → Donor-specific Immune Regulation by CD8+ Lymphocytes Expanded from Rejecting Human Cardiac Allografts(2008)9 cited
- → CD63 expression in metastatic melanoma and melanocytic nevi in lymph nodes(2021)1 cited
- Co-stimulatory molecules and FOXP3 mRNA expression in peripheral blood mononuclear cells in patients with chronic hepatitis B virus infection(2010)
- → Melanoma without Sentinel Lymph Node Involvement: Patients Have Increased Risk of Recurrence Detected by DecisionDx-Melanoma(2019)